ArticleCureus2026
Endovascular Salvage of Native Arteriovenous Fistulas: Post-Intervention Primary and Cumulative Patency Outcomes in a Colombian Regional Referral Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction
methodsWe conducted a retrospective observational study at a regional referral center in Colombia (January 2023-June 2025), including all adult patients undergoing endovascular salvage of arteriovenous fistulas (AVFs). Patients without salvage, with incomplete data, or under 18 years were excluded. Data were collected from electronic medical records and included demographic, clinical, anatomical, and procedural variables. Patency was assessed using a post-intervention approach, with time zero defined as the first endovascular procedure. Kaplan-Meier analysis was used to evaluate event-free survival (access loss or death) and overall survival, with follow-up censored at January 31, 2026. Descriptive and non-parametric statistical analyses were performed using RStudio (2024.12.1 + 563). The study was approved by the institutional ethics committee.
resultsFifty-nine patients (mean age 59 ± 13 years; 42/59 [71.2%] male) underwent 95 interventions. Hypertension (56/59 [94.9%]) and diabetes (27/59 [45.8%]) were the most common comorbidities. Brachiocephalic fistulas (44/59 [72.9%]) and left-sided access (39/59 [66.1%]) predominated. Technical success was achieved in all patients at the index intervention (100%). The mean interval between subsequent interventions was 162 days (5.4 months). Postintervention primary patency was approximately 65-70% at 180 days and declined progressively over time. Postintervention cumulative patency remained higher, with 75% at 600 days, 65-70% at 1000 days, and 30% at 1400-1500 days. No significant differences were observed by sex or treatment technique. Overall survival remained above 80% at 600 days and decreased gradually thereafter.
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.